Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
8053 | 1223 | 41.6 | 86% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
1197 | 8830 | 4 HYDROXYNONENAL//ISOPROSTANES//TOTAL POLAR COMPOUNDS |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | ISOPROSTANES | Author keyword | 122 | 45% | 17% | 205 |
2 | ISOPROSTANE | Author keyword | 56 | 43% | 8% | 101 |
3 | NEUROPROSTANES | Author keyword | 21 | 64% | 2% | 21 |
4 | PHYTOPROSTANES | Author keyword | 19 | 71% | 1% | 15 |
5 | F 2 ISOPROSTANE | Author keyword | 18 | 58% | 2% | 21 |
6 | F 2 ISOPROSTANES | Author keyword | 18 | 31% | 4% | 50 |
7 | 8 ISO PROSTAGLANDIN F 2 ALPHA | Author keyword | 17 | 55% | 2% | 21 |
8 | 8 EPI PGF2 ALPHA | Author keyword | 14 | 59% | 1% | 16 |
9 | IPF2 ALPHA III | Author keyword | 14 | 100% | 1% | 7 |
10 | CLAUDE PEPPER | Address | 13 | 34% | 3% | 32 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | ISOPROSTANES | 122 | 45% | 17% | 205 | Search ISOPROSTANES | Search ISOPROSTANES |
2 | ISOPROSTANE | 56 | 43% | 8% | 101 | Search ISOPROSTANE | Search ISOPROSTANE |
3 | NEUROPROSTANES | 21 | 64% | 2% | 21 | Search NEUROPROSTANES | Search NEUROPROSTANES |
4 | PHYTOPROSTANES | 19 | 71% | 1% | 15 | Search PHYTOPROSTANES | Search PHYTOPROSTANES |
5 | F 2 ISOPROSTANE | 18 | 58% | 2% | 21 | Search F+2+ISOPROSTANE | Search F+2+ISOPROSTANE |
6 | F 2 ISOPROSTANES | 18 | 31% | 4% | 50 | Search F+2+ISOPROSTANES | Search F+2+ISOPROSTANES |
7 | 8 ISO PROSTAGLANDIN F 2 ALPHA | 17 | 55% | 2% | 21 | Search 8+ISO+PROSTAGLANDIN+F+2+ALPHA | Search 8+ISO+PROSTAGLANDIN+F+2+ALPHA |
8 | 8 EPI PGF2 ALPHA | 14 | 59% | 1% | 16 | Search 8+EPI+PGF2+ALPHA | Search 8+EPI+PGF2+ALPHA |
9 | IPF2 ALPHA III | 14 | 100% | 1% | 7 | Search IPF2+ALPHA+III | Search IPF2+ALPHA+III |
10 | 8 ISO PGF2 ALPHA | 12 | 43% | 2% | 21 | Search 8+ISO+PGF2+ALPHA | Search 8+ISO+PGF2+ALPHA |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | 8 EPI PROSTAGLANDIN F2 ALPHA | 309 | 88% | 12% | 146 |
2 | ISOPROSTANES | 156 | 52% | 18% | 215 |
3 | F 2 ISOPROSTANES | 155 | 51% | 18% | 215 |
4 | NONCYCLOOXYGENASE | 154 | 73% | 10% | 117 |
5 | 8 ISO PROSTAGLANDIN F2 ALPHA | 112 | 62% | 9% | 116 |
6 | PROSTANOIDS F2 ISOPROSTANES | 93 | 78% | 5% | 61 |
7 | STRESS IN VIVO | 70 | 62% | 6% | 73 |
8 | RADICAL CATALYZED MECHANISM | 60 | 73% | 4% | 46 |
9 | 8 EPI PGF2 ALPHA | 49 | 78% | 3% | 32 |
10 | PEROXIDATION IN VIVO | 45 | 58% | 4% | 53 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
The isoprostanes-25 years later | 2015 | 5 | 212 | 68% |
Isoprostanes: markers and mediators of oxidative stress | 2004 | 302 | 105 | 75% |
Human biochemistry of the isoprostane pathway | 2008 | 90 | 43 | 84% |
F-2-isoprostanes in human health and diseases: From molecular mechanisms to clinical implications | 2008 | 108 | 258 | 60% |
Insights into oxidative stress: The isoprostanes | 2007 | 106 | 159 | 77% |
Systematic review on the association between F2-isoprostanes and cardiovascular disease | 2013 | 18 | 44 | 68% |
Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans | 2005 | 265 | 65 | 55% |
Isoprostanes: Formation, analysis and use as indices of lipid peroxidation in vivo | 1999 | 258 | 57 | 88% |
Quantification of F2-isoprostanes in biological fluids and tissues as a measure of oxidant stress | 2007 | 63 | 33 | 97% |
Using Isoprostanes as Biomarkers of Oxidative Stress: Some Rarely Considered Issues | 2010 | 57 | 104 | 56% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CLAUDE PEPPER | 13 | 34% | 2.6% | 32 |
2 | EXCELLENCE INFLAMMAT | 12 | 54% | 1.2% | 15 |
3 | UMR 5074 | 11 | 52% | 1.2% | 15 |
4 | UMR CNRS 5074 | 6 | 58% | 0.6% | 7 |
5 | CHIM BIOMOL INTERACT BIOL | 4 | 50% | 0.5% | 6 |
6 | FI TONE P HLTHASTHMA GRP | 4 | 75% | 0.2% | 3 |
7 | PHARMIBMMUMR 5247 | 4 | 75% | 0.2% | 3 |
8 | SECT CLIN NUTR | 3 | 24% | 0.9% | 11 |
9 | HSSRC | 3 | 32% | 0.6% | 7 |
10 | SECT GERIATR CLIN NUTR | 2 | 38% | 0.4% | 5 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000145964 | OXIDIZED PHOSPHOLIPIDS//LEVUGLANDIN//OX PAPC |
2 | 0.0000124164 | D ROMS TEST//D ROMS//OXIDAT |
3 | 0.0000098663 | MED BIOCHEM KURAMOTO CHO//4 ACETOXY 2 4 METHYLPHENYLBENZOTHIAZOLE//PHARMACEUT S KITA KU |
4 | 0.0000097215 | PRIMA CLIN MED//BIOMED EVOLUT AGING//CLIN LIPID |
5 | 0.0000085930 | EXHALED BREATH CONDENSATE//BREATH CONDENSATE//EXHALED BREATH TEMPERATURE |
6 | 0.0000069465 | MEMBRANE SCI//SANDERS BROWN AGING//REDOX PROTEOMICS |
7 | 0.0000063207 | CYCLOPENTENONE PROSTAGLANDINS//DELTA12 PROSTAGLANDIN J2//DELTA 12 PROSTAGLANDIN J2 |
8 | 0.0000056313 | DIPHENYL 1 PYRENYLPHOSPHINE//PHOSPHATIDYLCHOLINE HYDROPEROXIDE//HPLC CHEMILUMINESCENCE |
9 | 0.0000054445 | NITRO FATTY ACIDS//NITRATED FATTY ACIDS//NITRATED LIPIDS |
10 | 0.0000052641 | THROMBOXANE A2 RECEPTOR//THROMBOXANE RECEPTOR//THROMBOXANE A2 |